167 related articles for article (PubMed ID: 30635085)
21. Prediction of the responsiveness to pharmacological chaperones: lysosomal human alpha-galactosidase, a case of study.
Andreotti G; Guarracino MR; Cammisa M; Correra A; Cubellis MV
Orphanet J Rare Dis; 2010 Dec; 5():36. PubMed ID: 21138548
[TBL] [Abstract][Full Text] [Related]
22. The pharmacological chaperone N-n-butyl-deoxygalactonojirimycin enhances β-galactosidase processing and activity in fibroblasts of a patient with infantile GM1-gangliosidosis.
Mohamed FE; Al Sorkhy M; Ghattas MA; Al-Gazali L; Al-Dirbashi O; Al-Jasmi F; Ali BR
Hum Genet; 2020 May; 139(5):657-673. PubMed ID: 32219518
[TBL] [Abstract][Full Text] [Related]
23. A synthetic chaperone corrects the trafficking defect and disease phenotype in a protein misfolding disorder.
Yam GH; Zuber C; Roth J
FASEB J; 2005 Jan; 19(1):12-8. PubMed ID: 15629890
[TBL] [Abstract][Full Text] [Related]
24. Novel mutations of the GLA gene in Japanese patients with Fabry disease and their functional characterization by active site specific chaperone.
Shimotori M; Maruyama H; Nakamura G; Suyama T; Sakamoto F; Itoh M; Miyabayashi S; Ohnishi T; Sakai N; Wataya-Kaneda M; Kubota M; Takahashi T; Mori T; Tamura K; Kageyama S; Shio N; Maeba T; Yahagi H; Tanaka M; Oka M; Sugiyama H; Sugawara T; Mori N; Tsukamoto H; Tamagaki K; Tanda S; Suzuki Y; Shinonaga C; Miyazaki J; Ishii S; Gejyo F
Hum Mutat; 2008 Feb; 29(2):331. PubMed ID: 18205205
[TBL] [Abstract][Full Text] [Related]
25. Synergy between the pharmacological chaperone 1-deoxygalactonojirimycin and the human recombinant alpha-galactosidase A in cultured fibroblasts from patients with Fabry disease.
Porto C; Pisani A; Rosa M; Acampora E; Avolio V; Tuzzi MR; Visciano B; Gagliardo C; Materazzi S; la Marca G; Andria G; Parenti G
J Inherit Metab Dis; 2012 May; 35(3):513-20. PubMed ID: 22187137
[TBL] [Abstract][Full Text] [Related]
26. A comparative computational approach toward pharmacological chaperones (NN-DNJ and ambroxol) on N370S and L444P mutations causing Gaucher's disease.
Thirumal Kumar D; Iyer S; Christy JP; Siva R; Tayubi IA; George Priya Doss C; Zayed H
Adv Protein Chem Struct Biol; 2019; 114():315-339. PubMed ID: 30635084
[TBL] [Abstract][Full Text] [Related]
27. Treatment of Fabry's Disease with the Pharmacologic Chaperone Migalastat.
Germain DP; Hughes DA; Nicholls K; Bichet DG; Giugliani R; Wilcox WR; Feliciani C; Shankar SP; Ezgu F; Amartino H; Bratkovic D; Feldt-Rasmussen U; Nedd K; Sharaf El Din U; Lourenco CM; Banikazemi M; Charrow J; Dasouki M; Finegold D; Giraldo P; Goker-Alpan O; Longo N; Scott CR; Torra R; Tuffaha A; Jovanovic A; Waldek S; Packman S; Ludington E; Viereck C; Kirk J; Yu J; Benjamin ER; Johnson F; Lockhart DJ; Skuban N; Castelli J; Barth J; Barlow C; Schiffmann R
N Engl J Med; 2016 Aug; 375(6):545-55. PubMed ID: 27509102
[TBL] [Abstract][Full Text] [Related]
28. Identification of a novel loss-of-function mutation of the GLA gene in a Chinese Han family with Fabry disease.
Zhou C; Huang J; Cui G; Zeng H; Wang DW; Zhou Q
BMC Med Genet; 2018 Dec; 19(1):219. PubMed ID: 30587147
[TBL] [Abstract][Full Text] [Related]
29. Pharmacological chaperone therapy for Fabry disease.
Ishii S
Proc Jpn Acad Ser B Phys Biol Sci; 2012; 88(1):18-30. PubMed ID: 22241068
[TBL] [Abstract][Full Text] [Related]
30. The Large Phenotypic Spectrum of Fabry Disease Requires Graduated Diagnosis and Personalized Therapy: A Meta-Analysis Can Help to Differentiate Missense Mutations.
Citro V; Cammisa M; Liguori L; Cimmaruta C; Lukas J; Cubellis MV; Andreotti G
Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27916943
[TBL] [Abstract][Full Text] [Related]
31. Effects of pH and iminosugar pharmacological chaperones on lysosomal glycosidase structure and stability.
Lieberman RL; D'aquino JA; Ringe D; Petsko GA
Biochemistry; 2009 Jun; 48(22):4816-27. PubMed ID: 19374450
[TBL] [Abstract][Full Text] [Related]
32. A thermodynamic assay to test pharmacological chaperones for Fabry disease.
Andreotti G; Citro V; Correra A; Cubellis MV
Biochim Biophys Acta; 2014 Mar; 1840(3):1214-24. PubMed ID: 24361605
[TBL] [Abstract][Full Text] [Related]
33. Chaperone Therapy in Fabry Disease.
Weidemann F; Jovanovic A; Herrmann K; Vardarli I
Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163813
[TBL] [Abstract][Full Text] [Related]
34. Curcumin Has Beneficial Effects on Lysosomal Alpha-Galactosidase: Potential Implications for the Cure of Fabry Disease.
Monticelli M; Hay Mele B; Allocca M; Liguori L; Lukas J; Monti MC; Morretta E; Cubellis MV; Andreotti G
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674610
[TBL] [Abstract][Full Text] [Related]
35. Pharmacological chaperone therapy by active-site-specific chaperones in Fabry disease: in vitro and preclinical studies.
Germain DP; Fan JQ
Int J Clin Pharmacol Ther; 2009; 47 Suppl 1():S111-7. PubMed ID: 20040321
[TBL] [Abstract][Full Text] [Related]
36. Fabry disease: polymorphic haplotypes and a novel missense mutation in the GLA gene.
Ferri L; Guido C; la Marca G; Malvagia S; Cavicchi C; Fiumara A; Barone R; Parini R; Antuzzi D; Feliciani C; Zampetti A; Manna R; Giglio S; Della Valle CM; Wu X; Valenzano KJ; Benjamin R; Donati MA; Guerrini R; Genuardi M; Morrone A
Clin Genet; 2012 Mar; 81(3):224-33. PubMed ID: 21517827
[TBL] [Abstract][Full Text] [Related]
37. Mutation spectrum of α-Galactosidase gene in Japanese patients with Fabry disease.
Kobayashi M; Ohashi T; Kaneshiro E; Higuchi T; Ida H
J Hum Genet; 2019 Jul; 64(7):695-699. PubMed ID: 30988410
[TBL] [Abstract][Full Text] [Related]
38. Functional studies of new GLA gene mutations leading to conformational Fabry disease.
Filoni C; Caciotti A; Carraresi L; Cavicchi C; Parini R; Antuzzi D; Zampetti A; Feriozzi S; Poisetti P; Garman SC; Guerrini R; Zammarchi E; Donati MA; Morrone A
Biochim Biophys Acta; 2010 Feb; 1802(2):247-52. PubMed ID: 19941952
[TBL] [Abstract][Full Text] [Related]
39. Treatment of Fabry's Disease With Migalastat: Outcome From a Prospective Observational Multicenter Study (FAMOUS).
Lenders M; Nordbeck P; Kurschat C; Karabul N; Kaufeld J; Hennermann JB; Patten M; Cybulla M; Müntze J; Üçeyler N; Liu D; Das AM; Sommer C; Pogoda C; Reiermann S; Duning T; Gaedeke J; Stumpfe K; Blaschke D; Brand SM; Mann WA; Kampmann C; Muschol N; Canaan-Kühl S; Brand E
Clin Pharmacol Ther; 2020 Aug; 108(2):326-337. PubMed ID: 32198894
[TBL] [Abstract][Full Text] [Related]
40. Chaperone therapy update: Fabry disease, GM1-gangliosidosis and Gaucher disease.
Suzuki Y
Brain Dev; 2013 Jun; 35(6):515-23. PubMed ID: 23290321
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]